(firstQuint)A Phase 2 Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease.

 To determine the efficacy of Rituximab as first line of treatment of chronic GVHD.

 Efficacy will be defined as he ability to taper prednisone to a dose of 0.

25 mg/kg per day by 6 months without clinical or GVHD relapse/ recurrence.

.

 A Phase 2 Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease@highlight

The addition of rituximab to prednisone for the initial treatment of chronic GVHD will increase the overall response rate, enable a more rapid and effective steroid taper.

